Literature DB >> 15550475

Serum S-100B as an indicator of early postoperative deterioration after meningioma surgery.

George Stranjalis1, Stefanos Korfias, Christina Psachoulia, Efstathios Boviatsis, Andreas Kouyialis, Despina Protopappa, Damianos E Sakas.   

Abstract

BACKGROUND: S-100B protein is an established serum marker of primary and secondary brain damage in head injury and stroke. Despite major progress in neurophysiologic monitoring, there are still difficulties in the early identification and quantification of evolving edema or trauma after craniotomy for tumor. In this study we aimed to correlate serum S-100B values with early postoperative neurologic course as well as late outcome in meningioma surgery.
METHODS: We enrolled 50 consecutive patients who underwent meningioma resection. Serum S-100B was measured preoperatively and postcraniotomy for 7 consecutive days. Twenty-five patients (50%) developed immediate postoperative neurologic deterioration, and 15 (30%) had unfavorable 6-month outcomes. We used the Mann-Whitney U-test to assess the association of S-100B with all variables of interest. We used multiple logistic regression to search for the most significant predictor of postoperative deterioration.
RESULTS: Increased S-100B was highly correlated with larger tumors, intraoperative difficulties, postcraniotomy acute deterioration, and long-term poor outcome. In addition, multiple logistic regression showed that age, sex, site, preoperative edema, history of meningioma resection, extent of resection, and histologic type did not correlate with postoperative increases in S-100B. Furthermore, patients with postoperative S-100B values >0.4 microg/L had increased risk of deterioration (relative risk = 9.0; 95% confidence interval, 2.4-34; P <0.0001) and of poor ultimate outcome (relative risk = 11; 95% confidence interval, 1.6-77; P = 0.002).
CONCLUSIONS: After meningioma excision, postcraniotomy increases in serum S-100B appear to be an early indicator of short-term postoperative neurologic deterioration and of a poor longer-term outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550475     DOI: 10.1373/clinchem.2004.039719

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  Serum S100B levels after meningioma surgery: A comparison of two laboratory assays.

Authors:  Eyal Itshayek; Jeremy D Kark; Haim Ovadia; Carolyn F Weiniger; Yigal Shoshan; Sharon Einav
Journal:  BMC Clin Pathol       Date:  2008-09-19

2.  Early postoperative serum S100 beta levels predict ongoing brain damage after meningioma surgery: a prospective observational study.

Authors:  Sharon Einav; Yigal Shoshan; Haim Ovadia; Idit Matot; Moshe Hersch; Eyal Itshayek
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

3.  Transcriptomic Profiling Revealed Lnc-GOLGA6A-1 as a Novel Prognostic Biomarker of Meningioma Recurrence.

Authors:  Hanus Slavik; Vladimir Balik; Filip Zavadil Kokas; Rastislav Slavkovsky; Jana Vrbkova; Alona Rehulkova; Tereza Lausova; Jiri Ehrmann; Sona Gurska; Ivo Uberall; Marian Hajduch; Josef Srovnal
Journal:  Neurosurgery       Date:  2022-05-16       Impact factor: 5.315

Review 4.  S100 B: A new concept in neurocritical care.

Authors:  Omidvar Rezaei; Hossein Pakdaman; Kurosh Gharehgozli; Leila Simani; Amir Vahedian-Azimi; Sina Asaadi; Zahra Sahraei; Mohammadreza Hajiesmaeili
Journal:  Iran J Neurol       Date:  2017-04-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.